Skip to main content
Terug
Watch Compare

Lunai Bioworks Inc.

Datakwaliteit: 83%
LNAI
NASDAQ Manufacturing Chemicals
€ 0,37
▼ € 0,04 (-10,41%)
Marktkapitalisatie: 9,78 M
Prijs
€ 0,40
Marktkapitalisatie
9,78 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Negative free cash flow of -5,79 M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
N/A
ROICN/A
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
N/A
Current Ratio0,03
Interest Coverage-219,48

Waardering

PE (TTM)
-0,08
Boven sectorgemiddelde (-1,49)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1385 peers)
Metriek Aandeel Sector Mediaan
P/E -0,1 -1,5
P/B — 1,6
ROE % — -54,5
Net Margin % — -41,5
Rev Growth 5Y % — 1,9
D/E — 0,3

Koersdoel Analisten

Geen analistendekking beschikbaar

Winstschattingen

Geen toekomstige schattingen beschikbaar

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -125,52 M
ROE N/A ROA -1842,26%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -5,79 M
ROIC N/A FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 0,03
Interest Coverage -219,48 Asset Turnover N/A
Working Capital -19,49 M Tangible Book Value -19,65 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0,08 Forward P/E N/A
P/B Ratio N/A P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -59,21%
Market Cap 9,78 M Enterprise Value 9,29 M
Per Share
EPS (Diluted TTM) -0,72 Revenue / Share N/A
FCF / Share -0,24 OCF / Share -0,24
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 4,61%
SBC-Adj. FCF -6,86 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -178,01 M -80,65 M -39,68 M -113,43 M -26,72 M
EPS (Diluted) -1,08 -0,84 -0,71 — —
Gross Profit — — — — —
Operating Income -188,97 M -81,64 M -38,56 M -116,08 M -23,40 M
EBITDA — — — — —
R&D Expenses 537.428,0 2,71 M 4,17 M 8,37 M 15,54 M
SG&A Expenses — — — — —
D&A 129.095,0 121.859,0 113.496,0 123.590,0 123.535,0
Interest Expense 725.684,0 1,01 M 580.344,0 372.844,0 379.608,0
Income Tax 1.474,0 — 34,0 34,0 -125.276,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 8,23 M 163,13 M 58,30 M 84,63 M 189,61 M
Total Liabilities 29,58 M 31,15 M 11,80 M 12,01 M —
Shareholders' Equity -21,35 M 131,98 M 46,50 M 72,62 M 174,66 M
Total Debt — — — — —
Cash & Equivalents 92.700,0 220.467,0 1,87 M 9,17 M 20,66 M
Current Assets 1,05 M 2,00 M 2,57 M 9,57 M 20,90 M
Current Liabilities 29,16 M 30,31 M 11,02 M 6,45 M 1,89 M